Abstracts tagged "Health Care"

Abstract Number: 2106 • 2015 ACR/ARHP Annual Meeting
Intensification to Triple Therapy Non-Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States from 2009 to 2014
Jeffrey A. Sparks¹, Alexis A. Krumme², Olga S. Matlin³, Gregory Brill², William H. Shrank³, Niteesh K. Choudhry² and Daniel H. Solomon^2,4, ¹Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³CVS Caremark, Woonsocket, RI, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Several trials suggest that triple therapy with non-biologic disease-modifying antirheumatic drugs (ttDMARD) has similar efficacy compared to biologic DMARDs (bDMARD) for patients with RA.…
Abstract Number: 2259 • 2015 ACR/ARHP Annual Meeting
Incidence of Obesity, Diabetes and High Blood Pressure Associated with Arthritis: Analysis of the Canadian Longitudinal National Population Health Survey
Orit Schieir¹, Sheilah. Hogg-Johnson^1,2, Richard H Glazier^3,4,5,6 and Elizabeth M. Badley^1,7, ¹Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ²Institute for Work and Health, Toronto, ON, Canada, ³Family and Community Medicine, St. Michael's Hospital, Toronto, ON, Canada, ⁴Centre for Research on Inner City Health, St. Michael's Hospital, Toronto, ON, Canada, ⁵Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ⁶Family and Community Medicine, University of Toronto, Toronto, ON, Canada, ⁷Health Care & Outcomes Research, Toronto Western Res. Institute, Toronto, ON, Canada
Background/Purpose: While cross-sectional evidence points to a higher prevalence of cardiovascular (CVD) risk factors in persons with arthritis, longitudinal population based studies are lacking. The…
Abstract Number: 2914 • 2015 ACR/ARHP Annual Meeting
Modifiable and Non-Modifiable Correlates of Satisfaction with Care in Systemic Lupus Erythematosus
Syed Alam¹, Nisarg Gandhi², Alana Nevares¹, Ailda Nika², Winston Sequeira² and Meenakshi Jolly³, ¹Internal Medicine, Cook County Hospital, Chicago, IL, ²Rheumatology, Rush University Medical Center, Chicago, IL, ³Department of Medicine, Section of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Systemic Lupus Erythematosus (SLE) a chronic disease, predominantly of young women, which may involve various organs, and is marked by periods of disease flares,…
Abstract Number: 846 • 2015 ACR/ARHP Annual Meeting
Nationwide Trends in in-Hospital Mortality and Hospitalization Associated with Systemic Sclerosis (SSc)
Sara R. Schoenfeld¹, Na Lu¹, Flavia V. Castelino², Marcy B. Bolster² and Hyon K. Choi¹, ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Rheumatology, Allergy, Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Patients with systemic sclerosis (SSc) experience high rates of morbidity and mortality, but few studies have evaluated health care utilization such as hospitalization rates…
Abstract Number: 2939 • 2014 ACR/ARHP Annual Meeting
Increased Diagnosis of Spondyloarthritis in Female Patients Started in the Early Biologic Era
Nisha Nigil Haroon¹, Ping Li², Michael Paterson² and Nigil Haroon³, ¹Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Institute of Clinical Evaluative Sciences, Toronto, ON, Canada, ³Toronto Western Research Institute, Toronto, ON, Canada
Background/Purpose The health and economic impact of spondyloarthritis is considerable and growing. Over the past decade or more, there have been two major changes in…
Abstract Number: 2902 • 2014 ACR/ARHP Annual Meeting
The Health Status of Patients with Juvenile Idiopathic Arthritis (JIA) Significantly Worsens after Transfer from Pediatric to Adult Care
Kirsten Minden¹, Jens Klotsche², Martina Niewerth², Angela Zink³ and Gerd Horneff⁴, ¹Chidlrens´ hospital, Charité University Medicine, Berlin, Germany, ²Epidemiology unit, German Rheumatism Research Center, Berlin, Germany, ³German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ⁴Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany
Background/Purpose A minority of patients with polyarticular JIA enter adulthood in drug free remission. Thus, patients are in need of care beyond adolescence. There is…
Abstract Number: 2406 • 2014 ACR/ARHP Annual Meeting
Primary Non-Adherence, Associated Clinical Outcomes and Healthcare Resource Utilization Among Rheumatoid Arthritis Patients Prescribed Injectable Biologics
J. Harnett¹, D. Wiederkehr¹, R. Gerber², D. Gruben², J. Bourret³ and A. Koenig³, ¹Pfizer Inc, New York, NY, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Injectable biologics are commonly used to treat patients (pts) with moderate to severe rheumatoid arthritis (RA); the frequency with which they are prescribed but…
Abstract Number: 2116 • 2014 ACR/ARHP Annual Meeting
Hospitalization Rates and Utilization Among Rheumatoid Arthritis Patients: A Population-Based Study from 1987 to 2012
C. John Michet III¹, Katrina Strobova², Sara J. Achenbach³, Cynthia S. Crowson⁴ and Eric L. Matteson⁵, ¹Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, ²Department of Medicine, Charles University, Prague, Czech Republic, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Health Sciences Research, Mayo Clinic, Rochester, MN, ⁵Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose Patients with rheumatoid arthritis (RA) experience chronic management issues and are at risk for complex comorbidities. It is unknown, however, to what extent the…
Abstract Number: 2067 • 2014 ACR/ARHP Annual Meeting
Understanding the Factors Influencing Time to Diagnosis in Fibromyalgia
Howard Amital¹, Yaeli Bar-On², Varda Shalev³, Dahlia Weitzman³ and Gabriel Chodick⁴, ¹Department of Medicine B, Center for Autoimmune Diseases, Sheba Medical Center, Tel-hashomer, Israel, ²Department of Medicine E,, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, ³Medical Informatics, Maccabi Healthcare Services, Tel Aviv, Tel-Aviv, Israel, ⁴Medical Informatics, Healthcare Services, Tel Aviv, Tel-Aviv, Israel
Background/Purpose - Fibromyalgia (FM) is a chronic debilitating disorder considered to be part of a spectrum of central sensitization syndromes. The diagnosis of FM is…
Abstract Number: 2029 • 2014 ACR/ARHP Annual Meeting
Treatment Patterns of Multimorbid Rheumatoid Arthritis Patients: Results from an International Cross-Sectional Study
Helga Radner^1,2, Kazuki Yoshida^3,4, Ihsane Hmamouchi⁵, Maxime Dougados^6,7, Josef Smolen⁸ and Daniel H Solomon⁹, ¹Department of Internal Medicine III; Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, Kamogawa, Japan, ⁴Division of Rheumatology, Brigham and Women’s Hospital, Boston, MA, ⁵Biostatistics, Epidemiology LBRCE, Mohamed V Souissi University, Rabat, Morocco, ⁶Descartes University, Cochin Hospital, Paris, France, ⁷INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ⁸Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁹Rheumatology, Brigham and Women's Hospital, Boston, MA
Treatment Patterns of Multimorbid Rheumatoid Arthritis Patients: Results from an International Cross-sectional StudyBackground/Purpose The presence of multimorbidity could lead to less intensive treatment of RA.…
Abstract Number: 1693 • 2014 ACR/ARHP Annual Meeting
Progressive Disease in Systemic Sclerosis after One Year of Follow-up; Results of a Standardized Multidisciplinary Health Care Program
Jessica Meijs¹, Anne Schouffoer², Nina Ajmone Marsan³, Lucia Kroft⁴, Maarten K. Ninaber⁵, T.W.J. Huizinga¹ and Jeska K. De Vries-Bouwstra¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Cardiology, Leiden University Medical Center, Leiden, Netherlands, ⁴Deparment of Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁵Pulmonology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The aim of this study is to evaluate disease course of systemic sclerosis (SSc) patients participating in a single centre multidisciplinary health-care program over…
Abstract Number: 1299 • 2014 ACR/ARHP Annual Meeting
A Cross-Sectional Study of Mental Health Symptoms and Mental Health Care in Pediatric SLE/MCTD Patients and Their Peers
Andrea Knight^1,2, Michelle Vickery¹, Pamela Weiss^1,2,3, Knashawn Morales³ and Ron Keren^3,4, ¹Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ²Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ³Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, ⁴Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Mental health problems are prevalent in pediatric systemic lupus erythematosus (SLE). We aimed to compare the rates of mental health problems and mental health…
Abstract Number: 1145 • 2014 ACR/ARHP Annual Meeting
Evaluation of Biologic Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Post-Tumor Necrosis Factor Inhibitor Discontinuation in Rheumatoid Arthritis
J. Harnett¹, D. Wiederkehr¹, R. Gerber², D. Gruben², A. Koenig³ and J. Bourret³, ¹Pfizer Inc, New York, NY, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: For rheumatoid arthritis (RA) patients (pts) with inadequate response to a TNF inhibitor (TNFi), limited evidence exists from observational studies and indirect comparisons of…
Abstract Number: 903 • 2014 ACR/ARHP Annual Meeting
Poor Adherence to Medications for Systemic Lupus Erythematosus Predicts Higher Health Care Utilization in U.S. Medicaid Beneficiaries
Jinoos Yazdany¹, Candace H. Feldman², Hongshu Guan³ and Karen H. Costenbader⁴, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Rheumatology, Brigham and Women's Hospital, Boston, MA, ³Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Immunosuppressive and antimalarial drugs improve outcomes in systemic lupus erythematosus (SLE), including reducing disease activity, damage and mortality. Although prior studies have found…
Abstract Number: 800 • 2014 ACR/ARHP Annual Meeting
Hospitalization Rates and Utilization Among Patients with Giant Cell Arteritis: A Population-Based Study from 1987 to 2012
C. John Michet III¹, Sara J. Achenbach², Cynthia S. Crowson³ and Eric L. Matteson⁴, ¹Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose Patients with giant cell arteritis (GCA) may experience serious vascular and visual complications. It is unknown, however, to what extent the difficulties of the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].